Show simple item record

dc.contributor.authorMahajan, Raman
dc.contributor.authorDas, Pradeep
dc.contributor.authorIsaakidis, Petros
dc.contributor.authorSunyoto, Temmy
dc.contributor.authorSagili, Karuna D
dc.contributor.authorLima, Marıa Angeles
dc.contributor.authorMitra, Gaurab
dc.contributor.authorKumar, Deepak
dc.contributor.authorPandey, Krishna
dc.contributor.authorVan Geertruyden, Jean-Pierre
dc.contributor.authorBoelaert, Marleen
dc.contributor.authorBurza, Sakib
dc.date.accessioned2015-08-20T19:09:39Z
dc.date.available2015-08-20T19:09:39Z
dc.date.issued2015-06-30
dc.identifier.citationCombination Treatment for Visceral Leishmaniasis Patients Co-infected with Human Immunodeficiency Virus in India. 2015: Clin. Infect. Dis.en_GB
dc.identifier.issn1537-6591
dc.identifier.pmid26129756
dc.identifier.doi10.1093/cid/civ530
dc.identifier.urihttp://hdl.handle.net/10144/575416
dc.description.abstractThere are considerable numbers of patients co-infected with Human Immunodeficiency Virus (HIV) and Visceral Leishmaniasis (VL) in the VL-endemic areas of Bihar, India. These patients are at higher risk of relapse and death, but there are still no evidence-based guidelines on how to treat them. In this study, we report on treatment outcomes of co-infected patients up to 18 months following treatment with a combination regimen.
dc.languageENG
dc.language.isoenen
dc.publisherOxford University Pressen_GB
dc.rightsArchived with thanks to Clinical Infectious Diseases' open access policy: an official publication of the Infectious Diseases Society of Americaen_GB
dc.titleCombination Treatment for Visceral Leishmaniasis Patients Co-infected with Human Immunodeficiency Virus in Indiaen
dc.identifier.journalClinical Infectious Diseases : an official publication of the Infectious Diseases Society of Americaen_GB
refterms.dateFOA2019-03-04T12:33:49Z
html.description.abstractThere are considerable numbers of patients co-infected with Human Immunodeficiency Virus (HIV) and Visceral Leishmaniasis (VL) in the VL-endemic areas of Bihar, India. These patients are at higher risk of relapse and death, but there are still no evidence-based guidelines on how to treat them. In this study, we report on treatment outcomes of co-infected patients up to 18 months following treatment with a combination regimen.


Files in this item

Thumbnail
Name:
Mahajan R et al - 2015 - Combi ...
Size:
1.299Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record